3933.HK
3933.HK
KYG8813K1085
UNITED LAB
Loading chart...

Company Profile

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-infection, and other human-used finished products, including ophthalmic drugs, topical dermatological drugs, etc.; and health and wellness products, such as general dietary supplements, healthcare food products, cross-border nutritional supplements, and medical and aesthetic skincare products for various categories comprising bone and joint nutrition, intestinal regulation, cardiovascular health, vision protection, and immunity enhancement. Further, it is involved in the research and development, production, sale, and technical services of economic and companion animal medicines for livestock, poultry, and aquatic products and pets. The company has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The United Laboratories International Holdings Limited was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

Related stocks

HCM.L
HCM.L • Hong Kong SAR China
HUTCHMED (CHINA) LIMITED ORD US
203 GBp
2.33B USD 1Y -11.8%
HCM
HCM • Hong Kong SAR China
HUTCHMED (China) Limited
14.1 USD
2.45B USD 1Y -16.6%
RGC
RGC • Hong Kong SAR China
Regencell Bioscience Holdings L
7.35 USD
3.64B USD 1Y -60.7%
0512.HK
0512.HK • Hong Kong SAR China
GRAND PHARMA
4.74 HKD
2.12B USD 1Y -43.5%
2005.HK
2005.HK • Hong Kong SAR China
SSY GROUP
2.67 HKD
975.57M USD 1Y -10.6%
4540.T
4540.T • Japan
TSUMURA & CO
3,772 JPY
1.78B USD 1Y +5%
600216.SS
600216.SS • China
ZHEJIANG MEDICINE
12.59 CNY
1.81B USD 1Y -12.9%
600267.SS
600267.SS • China
ZHEJIANG HISUN PHARMACEUTICAL C
11.94 CNY
2.11B USD 1Y +13.5%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
46.4% p.a.
Max Drawdown (5Y)
-57.8%
Sharpe Ratio (5Y)
0.11
Beta Factor
0.30
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (46.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -66.2% in the extended horizon.
ende